← All drugs Report issue

mdx2004

mAbexperimentalTri-specific

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Oct 1, 2025 (NCT07110584)

Timeline

2020s

Jan 1, 2025
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Neoplasms · Phase 1/Phase 2

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainACTIVATOR
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
Tumor necrosis factor receptor superfamily member 9INHIBITOR
TNFRSF9 inhibitor
- Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) ↗
T-cell-specific surface glycoprotein CD28INHIBITOR
CD28 inhibitor
- T-cell-specific surface glycoprotein CD28 (CD28) ↗

Chemistry & pharmacology

Multi-specific: Yes (Tri-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07110584	Phase 1/Phase 2 (Phase 2)	Oct 1, 2025	Opko

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Opko	For profit	1	1	1	2025

1 organizations

Page 1 / 1